Your browser doesn't support javascript.
loading
Cálculo del impacto económico para Chile del uso de losartán en diabéticos tipo 2 con nefropatía diabética, basado en resultados del estudio RENAAL / Economic impact of Losartan use in type 2 diabetic patients with nephropathy
González F, Fernando; Fuentes C, Verónica; Castro H, Catalina; Santelices L, Juan Pablo; Lorca H, Eduardo.
  • González F, Fernando; Hospital del Salvador. Santiago. CL
  • Fuentes C, Verónica; s.af
  • Castro H, Catalina; Universidad de Chile. Facultad de Medicina. Campus Oriente. Santiago. CL
  • Santelices L, Juan Pablo; Universidad de Chile. Facultad de Medicina. Campus Oriente. Santiago. CL
  • Lorca H, Eduardo; Hospital del Salvador. Santiago. CL
Rev. méd. Chile ; 137(5): 634-640, mayo 2009. tab
Article in Spanish | LILACS | ID: lil-521865
ABSTRACT

Background:

The study RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) demonstrated that Losartan was more effective lo reduce the progression of kidney disease in diabetic patients with proteinuria and a reduction in glomerular filtration rate.

Aim:

To perform a cost benefit analysis of Losartan use from provider and payer points of view. Material and

methods:

Published data of the RENAAL study was analyzed. The costs of the use or not use of Losartan in patients with diabetic nephropathy were compared in terms of total costs of the disease including medications, hospital admissions for myocardial infarction, cerebrovascular accidents and congestive cardiac failure and the costs of chronic hemodialysis.

Results:

The reduction in antihypertensive medication use, hospital admissions, and the delay in dialysis requirement from a mean of 65 to 79 months induced by Losartan use, results in net savings of $7,576,135 per patient, at 3.5 years of intervention. The figure does not change using different sensitivity scenarios.

Conclusions:

The eventual use of Losartan in type 2 diabetic patients results in important savings.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Losartan / Angiotensin II Type 1 Receptor Blockers / Diabetic Nephropathies Type of study: Health economic evaluation Limits: Humans Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2009 Type: Article Affiliation country: Chile Institution/Affiliation country: Hospital del Salvador/CL / Universidad de Chile/CL

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Losartan / Angiotensin II Type 1 Receptor Blockers / Diabetic Nephropathies Type of study: Health economic evaluation Limits: Humans Country/Region as subject: South America / Chile Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2009 Type: Article Affiliation country: Chile Institution/Affiliation country: Hospital del Salvador/CL / Universidad de Chile/CL